{"preliminary_commentary":{"by_channel":{"x_thread":11,"podcast":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04951583\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"FMT-LUMINATE","nct_id":"NCT04951583","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fmt-luminate-nct04951583. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"FMT-LUMINATE","arms":[{"description":"Metastatic or advanced NSCLC: Single-agent Pembrolizumab (2 mg/kg or 200 mg every 3 weeks) in combination with investigational FMT capsules as follows: Full FMT at least 7 days prior to first cycle of Pembrolizumab.\n\nMetastatic melanoma and uveal melanoma: Combination therapy of Ipilimumab plus Nivolumab (Ipilimumab 3 mg/kg every 3 weeks and Nivolumab 1 mg/kg every 3 weeks x 4 doses, followed by Nivolumab 3 mg/kg or 240mg every 2 weeks or 6 mg/kg or 480mg every 4 weeks) in combination with investigational FMT capsules as follows: full FMT at least 7 days prior to first treatment with Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the second cycle with combination Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the third cycle of Ipilimumab plus Nivolumab.","label":"Immune checkpoint inhibitor (ICI) therapy in combination with fecal microbial transplantation (FMT).","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-09-01","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer Metastatic","Advanced Melanoma"],"enrollment":{"count":45,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"FMT + ICI","otherNames":[],"type":"COMBINATION_PRODUCT"}],"last_update":"2024-08-07","lead_sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","official_title":"Phase II Trial of Fecal Microbial Transplantation in Patients With Advanced Non-Small Cell Lung Cancer and Melanoma Treated With Immune Checkpoint Inhibitors.","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2024-09-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective response rate in the NSCLC cohort by RECIST criteria.","timeFrame":"up to 2 years"}],"references":[{"citation":"Duttagupta S, Messaoudene M, Hunter S, Desilets A, Jamal R, Mihalcioiu C, Belkaid W, Marcoux N, Fidelle M, Suissa D, Ponce M, Geiger M, Malo J, Piccinno G, Puncochar M, Filin A, Heidrich V, Rusu D, Mbaye B, Durand S, Ben Aissa I, Puller V, de Lahondes R, Blais N, Tehfe M, Owen S, Belanger K, Parvathy SN, Shieh B, Raphael J, Lenehan J, Breadner D, Rothenstein J, Rozza N, Maillou J, Nili S, Prifti DK, Pinto F, Armanini F, Kim-Schulze S, Marron TU, Kroemer G, Derosa L, Zitvogel L, Silverman M, Segata N, Maleki Vareki S, Routy B, Elkrief A. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nat Med. 2026 Apr;32(4):1337-1350. doi: 10.1038/s41591-025-04186-5. Epub 2026 Jan 28.","pmid":"41606121","type":"DERIVED"}],"start_date":{"date":"2021-11-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma","url":"https://clinicaltrials.gov/study/NCT04951583"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fmt-luminate-nct04951583"}